Paper29708331
Effects of the 1- N-(4-Amino-2 S-hydroxybutyryl) and 6'- N-(2-Hydroxyethyl) Substituents on Ribosomal Selectivity, Cochleotoxicity, and Antibacterial Activity in the Sisomicin Class of Aminoglycoside Antibiotics.
Sonousi A and 6 others. ACS Infect Dis, 2018. Cited by 22 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Effects of the 1- N-(4-Amino-2 S-hydroxybutyryl) and 6'- N-(2-Hydroxyethyl) Substituents on Ribosomal Selectivity, Cochleotoxicity, and Antibacterial Activity in the Sisomicin Class of Aminoglycoside Antibiotics. Papers, record 29708331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29708331
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Effects of the 1- N-(4-Amino-2 S-hydroxybutyryl) and 6'- N-(2-Hydroxyethyl) Substituents on Ribosomal Selectivity, Cochleotoxicity, and Antibacterial Activity in the Sisomicin Class of Aminoglycoside Antibiotics.
- PubMed
- Publication types
- Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Aminoglycosides | Major topic |
| Anti-Bacterial Agents | Major topic |
| Ribosomes | Major topic |
| Sisomicin | Major topic |
| Base Sequence | |
| Dose-Response Relationship, Drug | |
| Drug Evaluation, Preclinical | |
| Escherichia coli | |
| Humans | |
| Microbial Sensitivity Tests | |
| Protein Biosynthesis | |
| Structure-Activity Relationship |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| R01 AI123352 | NIAID NIH HHS | United States | R01AI123352 | PubMed and NIH |
Source NIH RePORTER
References47
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26,877,861 | Mechanisms of Resistance to Aminoglycoside Antibiotics: Overview and Perspectives. | Medchemcomm | 2016 | https://conductscience.org/library/papers/26877861 | PubMed |
| 2 | 22,699,498 | Dissociation of antibacterial activity and aminoglycoside ototoxicity in the 4-monosubstituted 2-deoxystreptamine apramycin. | Proc Natl Acad Sci U S A | 2012 | https://conductscience.org/library/papers/22699498 | PubMed |
| 3 | 25,209,664 | Structural basis for the inhibition of the eukaryotic ribosome. | Nature | 2014 | https://conductscience.org/library/papers/25209664 | PubMed |
| 4 | 4,143,427 | Structures and syntheses of aminoglycoside antibiotics. | Adv Carbohydr Chem Biochem | 1974 | https://conductscience.org/library/papers/4143427 | PubMed |
| 5 | 28,343,384 | N6', N6''', and O4' Modifications to Neomycin Affect Ribosomal Selectivity without Compromising Antibacterial Activity. | ACS Infect Dis | 2017 | https://conductscience.org/library/papers/28343384 | PubMed |
| 6 | 26,294,060 | Selective Protection of Secondary Amines as the N-Phenyltriazenes. Application to Aminoglycoside Antibiotics. | Org Lett | 2015 | https://conductscience.org/library/papers/26294060 | PubMed |
| 7 | 27,746,889 | Endless Resistance. Endless Antibiotics? | Medchemcomm | 2016 | https://conductscience.org/library/papers/27746889 | PubMed |
| 8 | 27,745,736 | Evaluation of apramycin activity against carbapenem-resistant and -susceptible strains of Enterobacteriaceae. | Diagn Microbiol Infect Dis | 2016 | https://conductscience.org/library/papers/27745736 | PubMed |
| 9 | 26,024,064 | Influence of 4'-O-Glycoside Constitution and Configuration on Ribosomal Selectivity of Paromomycin. | J Am Chem Soc | 2015 | https://conductscience.org/library/papers/26024064 | PubMed |
| 10 | 29,385,736 | Overcoming Aminoglycoside Enzymatic Resistance: Design of Novel Antibiotics and Inhibitors. | Molecules | 2018 | https://conductscience.org/library/papers/29385736 | PubMed |
| 11 | 25,837,512 | Ribosome. The complete structure of the 55S mammalian mitochondrial ribosome. | Science | 2015 | https://conductscience.org/library/papers/25837512 | PubMed |
| 12 | 413,921 | Semisynthetic aminoglycoside antibacterials. 6. Synthesis of sisomicin, Antibiotic G-52, and novel 6'-substituted analogues of sisomicin from aminoglycoside 66-40C. | J Med Chem | 1978 | https://conductscience.org/library/papers/413921 | PubMed |
| 13 | 21,282,439 | In vivo efficacy of the novel aminoglycoside ACHN-490 in murine infection models. | Antimicrob Agents Chemother | 2011 | https://conductscience.org/library/papers/21282439 | PubMed |
| 14 | 4,609,627 | The use of N-hydroxy-5-morbornene-2,3-dicarboximide active esters in peptide synthesis. | Chem Pharm Bull (Tokyo) | 1974 | https://conductscience.org/library/papers/4609627 | PubMed |
| 15 | 11,667,239 | Reductive Amination of Aldehydes and Ketones with Sodium Triacetoxyborohydride. Studies on Direct and Indirect Reductive Amination Procedures(1). | J Org Chem | 1996 | https://conductscience.org/library/papers/11667239 | PubMed |
| 16 | 22,512,755 | Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. | Expert Rev Anti Infect Ther | 2012 | https://conductscience.org/library/papers/22512755 | PubMed |
| 17 | 24,990,531 | The evolving role of chemical synthesis in antibacterial drug discovery. | Angew Chem Int Ed Engl | 2014 | https://conductscience.org/library/papers/24990531 | PubMed |
| 18 | 24,038,605 | Combating multidrug-resistant bacteria: current strategies for the discovery of novel antibacterials. | Angew Chem Int Ed Engl | 2013 | https://conductscience.org/library/papers/24038605 | PubMed |
| 19 | 20,805,391 | Synthesis and spectrum of the neoglycoside ACHN-490. | Antimicrob Agents Chemother | 2010 | https://conductscience.org/library/papers/20805391 | PubMed |
| 20 | 17,766,247 | Engineering the rRNA decoding site of eukaryotic cytosolic ribosomes in bacteria. | Nucleic Acids Res | 2007 | https://conductscience.org/library/papers/17766247 | PubMed |
Cited by18
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 22 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41,755,818 | G1405 Ribosomal Methyltransferase-Driven Antibacterial Resistance Affects the 4,5-Disubstituted-2-deoxystreptamine Class of Aminoglycoside Antibiotics. | JACS Au | 2026 | https://conductscience.org/library/papers/41755818 | PubMed |
| 41,383,247 | Plazomicin: A promising novel antimicrobial in the era of bacterial resistance (Review). | Exp Ther Med | 2026 | https://conductscience.org/library/papers/41383247 | PubMed |
| 40,384,761 | Strategic re-engineering of antibiotics. | Nat Rev Bioeng | 2025 | https://conductscience.org/library/papers/40384761 | PubMed |
| 39,211,618 | Decarboxylation in Natural Products Biosynthesis. | JACS Au | 2024 | https://conductscience.org/library/papers/39211618 | PubMed |
| 36,544,494 | Facile and selective N-alkylation of gentamicin antibiotics via chemoenzymatic synthesis. | Green Chem | 2022 | https://conductscience.org/library/papers/36544494 | PubMed |
| 34,117,352 | Structural basis for plazomicin antibiotic action and resistance. | Commun Biol | 2021 | https://conductscience.org/library/papers/34117352 | PubMed |
| 34,114,793 | Synthesis and Antibacterial Activity of Propylamycin Derivatives Functionalized at the 5''- and Other Positions with a View to Overcoming Resistance Due to Aminoglycoside Modifying Enzymes. | ACS Infect Dis | 2021 | https://conductscience.org/library/papers/34114793 | PubMed |
| 34,078,922 | Structural and phylogenetic analyses of resistance to next-generation aminoglycosides conferred by AAC(2') enzymes. | Sci Rep | 2021 | https://conductscience.org/library/papers/34078922 | PubMed |
| 33,288,712 | Dissociating antibacterial from ototoxic effects of gentamicin C-subtypes. | Proc Natl Acad Sci U S A | 2020 | https://conductscience.org/library/papers/33288712 | PubMed |
| 33,007,139 | An Advanced Apralog with Increased in vitro and in vivo Activity toward Gram-negative Pathogens and Reduced ex vivo Cochleotoxicity. | ChemMedChem | 2021 | https://conductscience.org/library/papers/33007139 | PubMed |
| 32,326,389 | Selective Modification of Streptozotocin at the C3 Position to Improve Its Bioactivity as Antibiotic and Reduce Its Cytotoxicity towards Insulin-Producing β Cells. | Antibiotics (Basel) | 2020 | https://conductscience.org/library/papers/32326389 | PubMed |
| 31,790,244 | Apralogs: Apramycin 5-O-Glycosides and Ethers with Improved Antibacterial Activity and Ribosomal Selectivity and Reduced Susceptibility to the Aminoacyltranserferase (3)-IV Resistance Determinant. | J Am Chem Soc | 2020 | https://conductscience.org/library/papers/31790244 | PubMed |
| 31,594,862 | Functionally critical residues in the aminoglycoside resistance-associated methyltransferase RmtC play distinct roles in 30S substrate recognition. | J Biol Chem | 2019 | https://conductscience.org/library/papers/31594862 | PubMed |
| 31,436,080 | Modification at the 2'-Position of the 4,5-Series of 2-Deoxystreptamine Aminoglycoside Antibiotics To Resist Aminoglycoside Modifying Enzymes and Increase Ribosomal Target Selectivity. | ACS Infect Dis | 2019 | https://conductscience.org/library/papers/31436080 | PubMed |
| 31,303,992 | Synthesis, ribosomal selectivity, and antibacterial activity of netilmicin 4'-derivatives. | Medchemcomm | 2019 | https://conductscience.org/library/papers/31303992 | PubMed |
| 31,057,735 | Synthesis of saccharocin from apramycin and evaluation of its ribosomal selectivity. | Medchemcomm | 2019 | https://conductscience.org/library/papers/31057735 | PubMed |
| 30,793,894 | Design, Multigram Synthesis, and in Vitro and in Vivo Evaluation of Propylamycin: A Semisynthetic 4,5-Deoxystreptamine Class Aminoglycoside for the Treatment of Drug-Resistant Enterobacteriaceae and Other Gram-Negative Pathogens. | J Am Chem Soc | 2019 | https://conductscience.org/library/papers/30793894 | PubMed |
| 30,447,062 | Aminoglycoside Revival: Review of a Historically Important Class of Antimicrobials Undergoing Rejuvenation. | EcoSal Plus | 2018 | https://conductscience.org/library/papers/30447062 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AGA | 175 | PubTator's text mining | https://conductscience.org/library/genes/175 | NCBI Gene |
| NAT2 | 10 | PubTator's text mining | https://conductscience.org/library/genes/10 | NCBI Gene |
| SLC25A6 | 293 | PubTator's text mining | https://conductscience.org/library/genes/293 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29708331
GET https://conductscience.org/api/papers/v1/29708331/references?page=2